Purchase Order 75N91018P00705

<p>The National Cancer Institute awarded a purchase order to Immunoscape Pte. LTD. for cytometry profiling service with a ceiling value of $12,907 on August 29, 2018. Performance is located in Singapore with an ultimate completion date of March 29, 2019. The order is firm fixed price with no set-aside designation.</p>

<p>The National Cancer Institute awarded a purchase order to Immunoscape Pte. LTD. for cytometry profiling service with a ceiling value of $22,302.00 on September 11, 2018. Work is performed in Singapore under firm fixed price terms. The order was completed October 30, 2019. No set-aside applied.</p>

<p>The National Cancer Institute awarded a purchase order to Miltenyi Biotec, Inc. for $5,631.00 on February 6, 2018, with ultimate completion on March 2, 2018. No set-aside was used. Work is performed in Bethesda, Maryland. The order is a firm fixed-price acquisition for specialized biotechnology equipment or consumables; the source does not specify the particular item or service line procured under this purchase order.</p>

<p>The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation for $14,274.88 on March 4, 2014, to perform T-cell receptor deep sequencing on 40 samples total. Performance is located in Bethesda, Maryland. The order is firm fixed price with an ultimate completion date of September 11, 2019.</p>

<p>The National Cancer Institute awarded a purchase order to Adaptive Biotechnologies Corporation for $20,850 on September 11, 2020, with final completion on December 11, 2020. The order covers laboratory testing services on a firm fixed-price basis with no set-aside designation. Work is performed in Bethesda, Maryland.</p>

<p>The National Cancer Institute awarded a purchase order to Miltenyi Biotec, Inc. for $4,111.00 on September 6, 2017, with completion scheduled for September 29, 2017. No set-aside was applied. Place of performance is Bethesda, Maryland. The order is firm fixed-price. Specific line-item details are not disclosed in the source.</p>

The National Cancer Institute awarded a purchase order to Olink Proteomics Inc. for $47,300.00 on July 21, 2026. Work is performed in Bethesda, Maryland. The order is firm fixed price with no set-aside and carries an ultimate completion date of July 20, 2027. The requirement involves proteomics analysis services focused on myelodysplastic syndromes, drawing on targeted proteomic arrays to identify protein biomarker changes in stem cell malignancies characterized by chronic inflammation,...

<p>The National Cancer Institute issued a delivery order to Becton, Dickinson and Company on April 5, 2026, for flow cytometric analysis reagents with a ceiling value of $13,243.25.</p> <p>Place of performance is Bethesda, MD 20892. The order has an ultimate completion date of April 5, 2026, and is priced as firm fixed price. No set-aside was used for this delivery order.</p>

<p>The National Cancer Institute awarded a purchase order to ProteinSimple for a capillary-based nano-immunoassay, valued at $25,000, on August 9, 2017. Performance is located in Bethesda, Maryland, with an ultimate completion date of December 31, 2017. The order is priced on a firm fixed-price basis with no set-aside designation.</p>

<p>The National Cancer Institute awarded a purchase order to Miltenyi Biotec, Inc. for laboratory supplies on April 26, 2018, with a ceiling value of $7,381.00 and an ultimate completion date of May 28, 2018. Performance is based in Auburn, California. The order is firm fixed price with no set-aside.</p>